AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23215944 — intervention group
Group type: EXPERIMENTAL
Intervention: Post Acc
Number of subjects: 10
Study 23215944 — intervention group
Group type: COMPARATOR
Intervention: Post Acc +PC
Number of subjects: 10
Study 23215944 — intervention group
Group type: EXPERIMENTAL
Intervention: Post Acc and Post Acc +PC
Number of subjects: 10
Study 21517867 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal school-based prevention program (13 sessions)
Number of subjects: 417
Study 21517867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 417
Study 18410562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (strains E/N, Oxy and Pen) administered at 2 x 10(10) colony forming units, orally twice daily during antibiotic treatment
Number of subjects: 240
Study 18410562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 18410562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus (strains E/N, Oxy and Pen)
Number of subjects: 240
Study 16934074 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruise alone
Number of subjects: 1000
Study 16934074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sore arm alone
Number of subjects: 1000
Study 16934074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue alone
Number of subjects: 1000
Study 16934074 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor reaction alone
Number of subjects: 1000
Study 16934074 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor reaction, fatigue, and sore arm together
Number of subjects: 1000
Study 15588134 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing room air
Number of subjects: 7
Study 15588134 — intervention group
Group type: COMPARATOR
Intervention: Breathing 12% O2 (hypoxic condition)
Number of subjects: 7
Study 12790964 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical injection sclerotherapy (Group 1)
Number of subjects: 25
Study 12790964 — intervention group
Group type: EXPERIMENTAL
Intervention: NP‐led advice, information and bowel habit retraining (Group 2)
Number of subjects: 25
Study 12790964 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 25
Study 9059471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (15 mg/day)
Number of subjects: 20
Study 9059471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8229491 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-1 preserved PRBC
Number of subjects: 16
Study 8229491 — intervention group
Group type: COMPARATOR
Intervention: CPDA-1 preserved PRBC
Number of subjects: 16
Study 3875955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedrest with additional intravenous infusion of glucose
Number of subjects: 49
Study 3875955 — intervention group
Group type: COMPARATOR
Intervention: Bedrest
Number of subjects: 49
Study 3875955 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal transcutaneous nerval stimulation
Number of subjects: 49
Study 3875955 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal oxygen inhalation
Number of subjects: 49
Study 3875955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral long-term tocolysis
Number of subjects: 49
Study 31869338 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-prime, pox virus boost strategy vaccination
Number of subjects: 0
Study 29059389 — intervention group
Group type: EXPERIMENTAL
Intervention: IMB model-based intervention plus nicotine replacement therapy
Number of subjects: 83
Study 29059389 — intervention group
Group type: COMPARATOR
Intervention: Facilitated referral to the state Quitline (Control)
Number of subjects: 83
Study 27010951 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician manager education about hypertension management
Number of subjects: 103
Study 25193393 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg)
Number of subjects: 695
Study 25193393 — intervention group
Group type: COMPARATOR
Intervention: 3 drugs given separately (control group)
Number of subjects: 695
Study 22525485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl nitrate (GTN) 0.4 mg
Number of subjects: 10
Study 20541170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiation (75 Gy) plus hysterectomy (RTH)
Number of subjects: 464
Study 20541170 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiation (75 Gy) and cisplatin (40 mg/m2) plus hysterectomy (RTCH)
Number of subjects: 464
Study 20541170 — intervention group
Group type: EXPERIMENTAL
Intervention: Good response patients (345; 74%) after RTH or RTCH
Number of subjects: 464
Study 17562035 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ES)
Number of subjects: 20
Study 17562035 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (CM)
Number of subjects: 20
Study 17562035 — intervention group
Group type: COMPARATOR
Intervention: Tracking Training (TR)
Number of subjects: 20
Study 17165335 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with human amniotic membrane (HAM)
Number of subjects: 28
Study 17165335 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with mitomycin C (MMC)
Number of subjects: 28
Study 12187222 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostate resection
Number of subjects: 141
Study 12187222 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 141
Study 12187222 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrovaporization
Number of subjects: 141
Study 10192668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetics and vasoconstrictors (phenylephrine 0.5%, 2% lidocaine jelly, 2% tetracaine, 14% benzocaine)
Number of subjects: 40
Study 10192668 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical lubricants only)
Number of subjects: 40
Study 7590720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% cream (5 grams daily for 3 days)
Number of subjects: 221
Study 7590720 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 221
Study 1969992 — intervention group
Group type: EXPERIMENTAL
Intervention: No-scalpel vasectomy
Number of subjects: 1203
Study 1969992 — intervention group
Group type: COMPARATOR
Intervention: Standard incisional vasectomy
Number of subjects: 1203
Study 91481 — intervention group
Group type: COMPARATOR
Intervention: 4 g L-tryptophan
Number of subjects: 6
Study 31033430 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, Attitude and Practice (KAP) regarding occupational noise exposure; scores above 75% defined as good knowledge and positive attitude, scores >50% defined as good practice.
Number of subjects: 253
Study 31033430 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of hearing protection devices.
Number of subjects: 253
Study 31033430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing conservation program implementation.
Number of subjects: 253
Study 31719084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention (17 weekly sessions delivered by trained community health workers, including text messaging and Motivational Interviewing training)
Number of subjects: 28
Study 31719084 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 28
Study 30188495 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist cooling (cool[on])
Number of subjects: 11
Study 30188495 — intervention group
Group type: COMPARATOR
Intervention: Control (control[off])
Number of subjects: 11
Study 26709933 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 times the MAC
Number of subjects: 8
Study 26709933 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 2.0 times the MAC
Number of subjects: 8
Study 25144437 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF (2 series of contract‐relax stretching)
Number of subjects: 70
Study 25144437 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (static stretching for 1 min)
Number of subjects: 70
Study 21916989 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (20 mg rabeprazole and 1 g amoxicillin, twice daily for the first 5 days, followed by 20 mg rabeprazole, 500 mg clarithromycin, and 500 mg metronidazole, twice daily for the remaining 5 days)
Number of subjects: 246
Study 21916989 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy (20 mg rabeprazole, 500 mg clarithromycin, and 1 g amoxicillin, twice daily for 7 days)
Number of subjects: 246
Study 21916989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapy groups
Number of subjects: 246
Study 19533009 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence pessary
Number of subjects: 266
Study 19533009 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy
Number of subjects: 266
Study 19533009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both incontinence pessary and behavioral therapy
Number of subjects: 266
Study 17601803 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint-induced movement therapy (mCIMT)
Number of subjects: 30
Study 17601803 — intervention group
Group type: COMPARATOR
Intervention: traditional rehabilitation (TR)
Number of subjects: 30
Study 15465623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial complex I mutations in PD
Number of subjects: 0
Study 12177587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose amisulpride (ASP)
Number of subjects: 126
Study 12177587 — intervention group
Group type: COMPARATOR
Intervention: Flupentixol (FPX)
Number of subjects: 126
Study 10373140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (omeprazole 1 mg/kg/day and amoxicillin 50 mg/kg; maximum, 2 g/day)
Number of subjects: 252
Study 10373140 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole 1 mg/kg/day or 2 mg/kg/day, amoxicillin 50 mg/kg; maximum, 2 g/day, and clarithromycin 20 mg/kg; maximum, 1 g/day)
Number of subjects: 252
Study 10373140 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (1 mg/kg/day or 2 mg/kg/day)
Number of subjects: 252
Study 10373140 — intervention group
Group type: COMPARATOR
Intervention: Rapid urease test
Number of subjects: 252
Study 10373140 — intervention group
Group type: COMPARATOR
Intervention: 13C‐urea breath test
Number of subjects: 252
Study 7888256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air inhalation during exercise testing
Number of subjects: 12
Study 7888256 — intervention group
Group type: COMPARATOR
Intervention: Room air during exercise testing
Number of subjects: 12
Study 2091873 — intervention group
Group type: EXPERIMENTAL
Intervention: Genapol stabilized human insulin (HOE 21 PH H‐TRONIN)
Number of subjects: 21
Study 2091873 — intervention group
Group type: COMPARATOR
Intervention: Neutral preparation of biosynthetic human insulin (BHI)
Number of subjects: 21
Study 319641 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 309
Study 319641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 30914385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU, 100 IU, 160 IU)
Number of subjects: 0
Study 30914385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28290994 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DAPT duration (12–24 months)
Number of subjects: 14963
Study 28290994 — intervention group
Group type: COMPARATOR
Intervention: Short DAPT duration (3–6 months)
Number of subjects: 14963
Study 28290994 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score
Number of subjects: 14963
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mA current, 1-mm probe depth
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mA current, 4-mm probe depth
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA current, 1-mm probe depth
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA current, 4-mm probe depth
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mA intensity
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA intensity
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm probe depth
Number of subjects: 64
Study 25679344 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA current
Number of subjects: 64
Study 22434361 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP at 15 cm H(2)O
Number of subjects: 23
Study 22434361 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical prediction of CBF change
Number of subjects: 23
Study 21289226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified yogurt drink (DY; containing 500 IU vitamin D(3) and 150 mg Ca/250 mL)
Number of subjects: 90
Study 21289226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D + calcium-fortified yogurt drink (DCY; containing 500 IU vitamin D(3) and 250 mg Ca/250 mL)
Number of subjects: 90
Study 21289226 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt drink (PY; containing no vitamin D and 150 mg Ca/250 mL)
Number of subjects: 90
Study 19337745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 125 mg (ACZ)
Number of subjects: 15
Study 19337745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg (SIL)
Number of subjects: 15
Study 19337745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 15
Study 17080879 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F Plus (Tokuyama Dental)
Number of subjects: 0
Study 17080879 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop (3M ESPE)
Number of subjects: 0
Study 17080879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saliva contamination)
Number of subjects: 0
Study 17080879 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-application of adhesives after drying or rinsing saliva
Number of subjects: 0
Study 15623613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 41
Study 15623613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15370949 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychiatric case management (PCM)
Number of subjects: 20
Study 15370949 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 10510926 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3040
Study 10510926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 7552182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment protocol A (within 12 hours before IRCM)
Number of subjects: 45
Study 7552182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment protocol B (for 72 hours before IRCM)
Number of subjects: 45
Study 2123559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 20
Study 2123559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6273028 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (mean dose 0.5 microgram daily)
Number of subjects: 17
Study 6273028 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 (dose 100 microgram daily)
Number of subjects: 17
Study 31046700 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.0 μg/kg/wk for 24 weeks
Number of subjects: 322
Study 31046700 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5 μg/kg/wk for 24 weeks
Number of subjects: 322
Study 31046700 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b 1.5 μg/kg/wk for 48 weeks
Number of subjects: 322
Study 31046700 — intervention group
Group type: COMPARATOR
Intervention: No further NA treatment after EOS
Number of subjects: 322
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: PVO-associated SND
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: High Charlson index
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ASIA impairment scale at diagnosis
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal cord compression
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural abscess
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical involvement
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic involvement
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus PVO
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP >150 mg/L
Number of subjects: 394
Study 28538361 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of antibiotic treatment
Number of subjects: 394
Study 25856469 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/d)
Number of subjects: 240
Study 25856469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 23479383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus concomitant boost radiotherapy
Number of subjects: 22
Study 21849598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 portions of farmed salmon/wk
Number of subjects: 123
Study 21849598 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 123
Study 18800142 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3000
Study 18800142 — intervention group
Group type: COMPARATOR
Intervention: Conventional anti-hypertensive treatment
Number of subjects: 3000
Study 17923541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide drops applied 3 times a day for 4 weeks
Number of subjects: 20
Study 17923541 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops applied 3 times a day for 4 weeks
Number of subjects: 20
Study 17923541 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 20
Study 17923541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15519794 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein for 7 weeks
Number of subjects: 100
Study 15519794 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 100
Study 11305153 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0
Study 11305153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication
Number of subjects: 0
Study 11305153 — intervention group
Group type: COMPARATOR
Intervention: Conventional open fundoplication
Number of subjects: 0
Study 9773780 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking two cigarettes
Number of subjects: 22
Study 9773780 — intervention group
Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 22
Study 9773780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum
Number of subjects: 22
Study 9773780 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in patients with IgA glomerulonephritis
Number of subjects: 22
Study 9773780 — intervention group
Group type: COMPARATOR
Intervention: Smoking in all volunteers (n=35) vs patients (n=7)
Number of subjects: 22
Study 7836707 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin, 4000 U daily SQ for 7-20 days
Number of subjects: 19
Study 7836707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7836707 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 19
Study 31655965 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-based play-drama intervention
Number of subjects: 23
Study 31655965 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 23
Study 30534176 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic visceral manipulation (OVM); treatment group (OVMG)
Number of subjects: 28
Study 30534176 — intervention group
Group type: COMPARATOR
Intervention: Placebo visceral manipulation (PVM); control group (PVMG)
Number of subjects: 28
Study 27906935 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg daily (group I)
Number of subjects: 58
Study 27906935 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (group II)
Number of subjects: 58
Study 23984946 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactivation during sleep
Number of subjects: 0
Study 23984946 — intervention group
Group type: COMPARATOR
Intervention: Sleep without reactivation
Number of subjects: 0
Study 23984946 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sleep time
Number of subjects: 0
Study 23984946 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional reactivation by cueing during sleep
Number of subjects: 0
Study 22720283 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted implant‐retained overdenture (IOD)
Number of subjects: 60
Study 22720283 — intervention group
Group type: COMPARATOR
Intervention: Relined conventional denture (RCD)
Number of subjects: 60
Study 20072064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending back squat protocol (5 reps at 30% 1RM, 3 reps at 70% 1RM, 3 reps at 90% 1RM)
Number of subjects: 12
Study 20072064 — intervention group
Group type: COMPARATOR
Intervention: Control session (rest for 5 minutes before horizontal plyometric tests)
Number of subjects: 12
Study 19058074 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's screening recommendation
Number of subjects: 0
Study 19058074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer barriers, better knowledge, and more positive beliefs toward screening
Number of subjects: 0
Study 16331116 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 66
Study 16331116 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended release 5 mg/day
Number of subjects: 66
Study 16331116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12827099 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Communication Intervention (HCI)
Number of subjects: 35